[Respiratory syncytial virus infections and preventive options].
Respiratory syncytial virus (RSV) is the most prominent pathogen found in respiratory tract infections in children and the most important cause of bronchiolitis in the first two years of life. In the Netherlands approximately 2000 children are admitted each winter season. A serious course is mostly seen in children younger than 3 months, (ex-)prematures, children with bronchopulmonary dysplasia or congenital cardiac anomalies, children with cystic fibrosis younger then 2 years and children with impaired T cell immunity; such cases not rarely require intensive care. Treatment (fluid, nutrition, bronchodilator agents, corticosteroids, oxygen and ventilation) is usually symptomatic. Antiviral therapy is only indicated in immunodeficient patients. For prevention by passive immunization palivizumab was recently registered in the Netherlands, a monoclonal antibody against RSV that has to be administered intramuscularly from the start of the RSV season (15 mg per kg bodyweight once a month during five months). In a number of large-scale American multicenter studies both the number of hospital admissions related to RSV infection and the mean duration of hospital stay showed a statistically significant reduction in high-risk children who had been treated with palivizumab. Palivizumab appears to be indicated in children from the categories with an increased risk for serious RSV disease.
Rothbarth
P H
PH
Laboratorium Microbiologie Twente Achterhoek, Enschede.
Kimpen
J L
JL
Roord
J J
JJ
Neijens
H J
HJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007167:Immunotherapy; D015994:Incidence; D007902:Length of Stay / Q000706:statistics & numerical data; D009426:Netherlands / Q000453:epidemiology; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069455:Palivizumab